Affinia Therapeutics is an innovative gene therapy company focused on broadening the reach of gene therapy. Our proprietary Affinia Rationally-designed Therapies (ART) platform is created to address key limitations of conventional gene therapies, by developing novel capsids, novel promoters, and novel manufacturing approaches to developing gene therapies for rare and prevalent devastating diseases. We are backed by a strong syndicate of life science investors and have ambitious plans to have a dramatic impact on the lives of patients around the world.
As an early employee you will play a key role in setting our culture and values. You will be working alongside the founding management team who have a track record of success in the industry. The pace of work is dynamic, fast and fun.
We offer competitive salary and benefits with the ability to make a difference.
As an early employee you will play a key role in setting our culture and values. You will be working alongside the founding management team who have a track record of success in the industry. The pace of work is dynamic, fast and fun.
We offer competitive salary and benefits with the ability to make a difference.
Location: United States, Massachusetts, Waltham
Employees: 51-200
Total raised: $170M
Founded date: 2019
Investors 10
Funding Rounds 2
| Date | Series | Amount | Investors |
| 04.05.2021 | Series B | $110M | - |
| 01.04.2020 | Series A | $60M | - |
Mentions in press and media 14
| Date | Title | Description |
| 10.09.2024 | Affinia Therapeutics Announces the Appointment of Rami Daoud as Chief Business and Financial Officer | Industry veteran Daoud brings more than 25 years' experience in business development and corporate finance and strategy at multiple leading biopharmaceutical organizations WALTHAM, Mass., Sept. 10, 2024 /PRNewswire/ -- Affinia Therapeutics ... |
| 04.01.2022 | Gene therapy biotech Affinia Therapeutics files for a $100 million IPO | - |
| 14.12.2021 | Affinia Therapeutics Appoints Thomas Leggett as Chief Financial Officer | WALTHAM, Mass., Dec. 14, 2021 (GLOBE NEWSWIRE) -- Affinia Therapeutics, an innovative gene therapy company with a proprietary platform for rationally-designed adeno-associated virus (AAV) gene therapies for rare and prevalent devastating di... |
| 08.09.2021 | Affinia Therapeutics Announces Indications for Lead Gene Therapy Programs to Advance the Treatment of Neurologic and Neuro-oncologic Diseases supported by Multi-Year Manufacturing Agreement with Lonza... | Indications include metachromatic leukodystrophy, a rare, progressive, and fatal disease affecting the nervous system, and brain metastases secondary to HER2+ breast cancer, a common and deadly form of cancer – Affinia Therapeutics to use i... |
| 04.05.2021 | Affinia Therapeutics secures $110M | Affinia Therapeutics has raised a $110 million Series B co-led by EcoR1 Capital and Farallon Capital Management. Founded in 2019 and based in the Boston area, the company is developing gene therapies for diseases affecting the central nervo... |
| 04.05.2021 | Affinia Therapeutics raises $110 million for gene therapy treatments | Affinia Therapeutics, a Waltham-based biotech working on gene therapies to treat diseases using technology developed at Massachusetts Eye and Ear, said Monday it has raised $110 million in a new venture capital round. The company, which was... |
| 03.05.2021 | Affinia Therapeutics Closes $110 Million Series B Financing | - |
| 03.05.2021 | Affinia Therapeutics Closes $110 Million Series B Financing | Financing co-led by EcoR1 Capital and Farallon Capital Management Proceeds to support continued development of proprietary platform for rationally designed adeno-associated virus vectors (AAV) and advance programs into the clinic WALTHAM, M... |
| 03.05.2021 | Affinia Therapeutics Closes $110 Million Series B Financing | - |
| 01.04.2020 | Affinia Therapeutics Raises $60M in Series A Financing | Affinia Therapeutics, a Waltham, Mass.-based gene therapy company, closed a $60m Series A financing. The round was co-led by F-Prime Capital and New Enterprise Associates alongside new investor Atlas Venture, with participation from seed in... |
Show more